A novel mRNA nanovaccine with dual immunoregulation ameliorates rheumatoid arthritis and associated pneumonia

Jingjing Su , Wenguang Huang , Wenying Zhang , Ziyi Wang , Hongzhou Gu , Pengchao Sun , Yongxing Zhao

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101120

PDF (8161KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101120 DOI: 10.1016/j.ajps.2026.101120
Research Article
research-article
A novel mRNA nanovaccine with dual immunoregulation ameliorates rheumatoid arthritis and associated pneumonia
Author information +
History +
PDF (8161KB)

Abstract

Rheumatoid arthritis (RA) as a systemic autoimmune disease, frequently triggers various extra-articular symptoms, particularly the RA-associated pneumonia. Unfortunately, the RA-associated pneumonia has garnered insufficient attention, and conventional RA therapies may exacerbate pneumonia-related complications, thereby complicating the treatment process. Herein, a novel dual immunoregulatory mRNA nanovaccine (MPDA@RC@HM) is designed for the efficient treatment of RA and RA-associated pneumonia simultaneously. This innovative mRNA nanovaccine represents a highly organized nanostructure that integrates the rapamycin-loaded mesoporous polydopamine (MPDA) with mRNA encoding the epitope of type Ⅱ collagen, and the surface is modified with hyaluronic acid and dendritic cell membrane. After intravenous injection into collagen-induced arthritis mice, the mRNA nanovaccine exhibits effective distribution and transfection within the spleen and lung, subsequently exerting potent immunoregulation in both organs, thereby yielding a dual therapeutic effect. This study presents a versatile mRNA nanovaccine platform for the treatment of autoimmune diseases and provides an innovative approach for addressing RA and RA-associated pneumonia.

Keywords

Rheumatoid arthritis / Pneumonia / mRNA nanovaccine / Immunoregulation

Cite this article

Download citation ▾
Jingjing Su, Wenguang Huang, Wenying Zhang, Ziyi Wang, Hongzhou Gu, Pengchao Sun, Yongxing Zhao. A novel mRNA nanovaccine with dual immunoregulation ameliorates rheumatoid arthritis and associated pneumonia. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101120 DOI:10.1016/j.ajps.2026.101120

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Ding Q, Hu W, Wang R, Yang QY, Zhu ML, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther 2023; 8(1): 68.

[2]

Takeuchi T. Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases-RA as a role model. Inflamm Regen 2022; 42(1): 35.

[3]

Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 2021; 20(4): 102776.

[4]

Akiyama M, Alshehri W, Kaneko Y. Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist? Autoimmun Rev 2024; 23(2): 103501.

[5]

Koduri G, Solomon JJ. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2023; 75(12): 2067-77.

[6]

Sebastiani M, Manfredi A, Cassone G, Sandri G, Cerri S, Ferri C. Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients. Clin Exp Rheumatol 2017; 35(3): 542.

[7]

Kim A, Xie F, Abed OA, Moon JJ. Vaccines for immune tolerance against autoimmune disease. Adv Drug Deliv Rev 2023; 203: 115140.

[8]

Verbeke R, Hogan MJ, Loré K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity 2022; 55(11): 1993-2005.

[9]

Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 2021; 371(6525): 145-53.

[10]

Xu X, Wang X, Liao Y-P, Luo L, Xia T, Nel AE. Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single-and multiple-epitope nucleotide sequence delivery. ACS nano 2023; 17(5): 4942-57.

[11]

Zhang N, Li M, Hou Z, Ma L, Younas A, Wang Z, et al. From vaccines to nanovaccines: a promising strategy to revolutionize rheumatoid arthritis treatment. J Control Release 2022; 350: 107-21.

[12]

Romero-Castillo L, Li T, Do NN, Sareila O, Xu B, Hennings V, et al. Human MHC class II and invariant chain knock-in mice mimic rheumatoid arthritis with allele restriction in immune response and arthritis association. Adv Sci 2024; 11(23): 2401513.

[13]

Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007; 7(1): 65-70.

[14]

Xinqiang S, Fei L, Nan L, Yuan L, Hong X, Fang Y, et al. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+ CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine 2009; 27(5): 690-700.

[15]

Moten D, Teneva I, Apostolova D, Batsalova T, Dzhambazov B. Molecular mimicry of the rheumatoid arthritis-related immunodominant T-cell epitope within type II collagen (CII260-270) by the bacterial L-asparaginase. Int J Mol Sci 2022; 23(16): 9149.

[16]

Zhu P, Li X, Ding J, Fan C, Wang Y, Wang H, et al. Simultaneous detection of DNA synthesis, activation and cytokine secretion in collagen II (250-270)-activated T lymphocytes by flow cytometry. Cell Biol Int 2004; 28(11): 765-72.

[17]

Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J, et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 2007; 122(1): 75-84.

[18]

Hsu JC, Liu P, Song Y, Song W, Saladin RJ, Peng Y, et al. Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond. Chem Soc Rev 2024; 53(15): 7657-80.

[19]

Zhu M, Shi Y, Shan Y, Guo J, Song X, Wu Y, et al. Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics. J Nanobiotechnol 2021; 19(1): 387.

[20]

Wang T, Wang Y, Zhang Y, Fang Z, Li S, Gu Z, et al. Drug-loaded mesoporous polydopamine nanoparticles in chitosan hydrogels enable myocardial lnfarction repair through ROS scavenging and inhibition of apoptosis. ACS Appl Mater Interfaces 2024; 16(45): 61551-64.

[21]

Phan NM, Nguyen TL, Min DK, Kim J. Mesoporous polydopamine nanoparticle-based tolerogenic vaccine induces antigen-specific immune tolerance to prevent and treat autoimmune multiple sclerosis. Biomaterials 2025; 316: 122997.

[22]

Stabler CL, Li Y, Stewart JM, Keselowsky BG. Engineering immunomodulatory biomaterials for type 1 diabetes. Nat Rev Mater 2019; 4(6): 429-50.

[23]

Jung M, Lee S, Park S, Hong J, Kim C, Cho I, et al. A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer’s disease. Adv Mater 2023; 35(3): 2207719.

[24]

Cao Y, Long J, Sun H, Miao Y, Sang Y, Lu H, et al. Dendritic cell-mimicking nanoparticles promote mRNA delivery to lymphoid organs. Adv Sci 2023; 10(33): 2302423.

[25]

Marchal-Sommé J, Uzunhan Y, Marchand-Adam S, Kambouchner M, Valeyre D, Crestani B, et al. Dendritic cells accumulate in human fibrotic interstitial lung disease. Am J Respir Crit Care Med 2007; 176(10): 1007-14.

[26]

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547(7662): 222-6.

[27]

He Y, Zhang S, She Y, Liu Z, Zhu Y, Cheng Q, et al. Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy. Exploration 2024; 4(6): 20230164.

[28]

He T, Tang C-k, Xu S, Moyana TN, Xiang J. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cell Mol Immunol 2007; 4(2): 105-11.

[29]

Ge P, Chang S, Wang T, Zhao Q, Wang G, He B. An antioxidant and antibacterial polydopamine-modified thermo-sensitive hydrogel dressing for Staphylococcus aureus-infected wound healing. Nanoscale 2023; 15(2): 644-56.

[30]

Ou Q, Zhang S, Fu C, Yu L, Xin P, Gu Z, et al. More natural more better: triple natural anti-oxidant puerarin/ferulic acid/polydopamine incorporated hydrogel for wound healing. J Nanobiotechnol 2021; 19(1): 237.

[31]

Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007; 2(5): 1269-75.

[32]

Qiu F, Xie D, Chen H, Wang Z, Huang J, Cao C, et al. Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis. Ann Rheum Dis 2025; 84(5): 726-45.

[33]

Konkimalla A, Konishi S, Macadlo L, Kobayashi Y, Farino ZJ, Miyashita N, et al. Transitional cell states sculpt tissue topology during lung regeneration. Cell Stem Cell 2023; 30(11): 1486-1502.e9.

[34]

Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28(5): 511-15.

[35]

Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev 2021; 170: 83-112.

[36]

Zhang M, Wang Y, Li B, Yang B, Zhao M, Li B, et al. STING-activating polymers boost lymphatic delivery of mRNA vaccine to potentiate cancer immunotherapy. Adv Mater 2025; 37(10): 2412654.

[37]

Peng L, Hung CT, Wang S, Zhang X, Zhu X, Zhao Z, et al. Versatile nanoemulsion assembly approach to synthesize functional mesoporous carbon nanospheres with tunable pore sizes and architectures. J Am Chem Soc 2019; 141(17): 7073-80.

[38]

Meng Y, Liu P, Zhou W, Ding J, Liu J. Bioorthogonal DNA adsorption on polydopamine nanoparticles mediated by metal coordination for highly robust sensing in serum and living cells. ACS Nano 2018; 12(9): 9070-80.

[39]

Betker JL, Gomez J, Anchordoquy TJ. The effects of lipoplex formulation variables on the protein corona and comparisons with in vitro transfection efficiency. J Control Release 2013; 171(3): 261-8.

[40]

Liu Z, Lin W, Liu Y. Macrocyclic supramolecular assemblies based on hyaluronic acid and their biological applications. Acc Chem Res 2022; 55(23): 3417-29.

[41]

Mishra RK, Ahmad A, Vyawahare A, Alam P, Khan TH, Khan R. Biological effects of formation of protein corona onto nanoparticles. Int J Biol Macromol 2021; 175: 1-18.

[42]

Mrksich K, Padilla MS, Mitchell MJ. Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Adv Drug Deliv Rev 2024; 214: 115446.

[43]

Zhang M, Shao W, Yang T, Liu H, Guo S, Zhao D, et al. Conscription of immune cells by light-activatable silencing NK-derived exosome (LASNEO) for synergetic tumor eradication. Adv Sci 2022; 9(22): 2201135.

[44]

Fang Y, Ma B, Zhao Z, Xuan Z, Wang Y, Huang C, et al. mRNA-based FRET-FLIM imaging platform for quantifying lipid nanoparticle endosomal escape and membrane damage. J Am Chem Soc 2025; 147(34): 30907-23.

[45]

Hanyong W, Xinyu Y, Chunyan H, Chenlu H, Hai W, Dunwan Z, et al. Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy. Chin Chem Lett 2022; 33(9): 4179-84.

[46]

Saksida T, Jevti´c B, Djedovi´c N, Miljkovi´c Đ, Stojanovi´c I. Redox regulation of tolerogenic dendritic cells and regulatory T cells in the pathogenesis and therapy of autoimmunity. Antioxid Redox Signal 2021; 34(5): 364-82.

[47]

Qi W, Jin L, Huang S, Aikebaier A, Xue S, Wang Q, et al. Modulating synovial macrophage pyroptosis and mitophagy interactions to mitigate osteoarthritis progression using functionalized nanoparticles. Acta Biomater 2024; 181: 425-39.

[48]

Dangkoub F, Sankian M, Tafaghodi M, Jaafari MR, Badiee A. The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. J Control Release 2021; 339:: 274-283.

[49]

Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7(1): 33-42.

[50]

Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol 2022; 13: 867260.

[51]

Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012; 14: 1-16.

[52]

Cai X, Jin M, Yao L, He B, Ahmed S, Safdar W, et al. Physicochemical properties, pharmacokinetics, toxicology and application of nanocarriers. J Mater Chem B 2023; 11(4): 716-33.

[53]

Sato T, Satooka H, Ichioka S, Maruo Y, Hirata T. Citrullinated fibrinogen is a target of auto-antibodies in interstitial lung disease in mice with collagen-induced arthritis. Int Immunol 2020; 32(8): 533-45.

[54]

Formosa LE, Muellner-Wong L, Reljic B, Sharpe AJ, Jackson TD, Beilharz TH, et al. Dissecting the roles of mitochondrial complex I intermediate assembly complex factors in the biogenesis of complex I. Cell Rep 2020; 31(3): 107541.

[55]

Abramov AY, Angelova PR. Cellular mechanisms of complex I-associated pathology. Biochem So Trans 2019; 47(6): 1963-9.

[56]

Singh E, Gupta A, Singh P, Jain M, Muthukumaran J, Singh RP, et al. Exploring mammalian heme peroxidases: a comprehensive review on the structure and function of myeloperoxidase, lactoperoxidase, eosinophil peroxidase, thyroid peroxidase and peroxidasin. Arch Biochem Biophys 2024; 761: 110155.

[57]

Roumeguère T, Noyon C, Van Antwerpen P, Poelvoorde P, Bar I, Abdulsater F, et al. Role of myeloperoxidase in ROS generation and inflammation response on prostate epithelial cells. Inflammation 2023; 46(5): 1859-70.

[58]

Zhao X, Long J, Liang F, Liu N, Sun Y, Xi Y. Different protective efficacies of a novel antigen-specific DNA vaccine encoding chicken type Ⅱ collagen via intramuscular, subcutaneous, and intravenous vaccination against experimental rheumatoid arthritis. Biomed Pharmacother 2021; 144: 112294.

[59]

Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, et al. CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol 2010; 10(4): 412-21.

[60]

Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022; 7(1): 166.

PDF (8161KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉